CA2987708A1 - Procede de preparation de precurseur d'ibrutinib - Google Patents
Procede de preparation de precurseur d'ibrutinib Download PDFInfo
- Publication number
- CA2987708A1 CA2987708A1 CA2987708A CA2987708A CA2987708A1 CA 2987708 A1 CA2987708 A1 CA 2987708A1 CA 2987708 A CA2987708 A CA 2987708A CA 2987708 A CA2987708 A CA 2987708A CA 2987708 A1 CA2987708 A1 CA 2987708A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- boc
- cbz
- ibrutinib
- arylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention concerne un procédé de préparation de précurseur d'ibrutinib, 3-(4-phénoxyphényl)-1-((3R)-pipéridin-3-yl)-1H-pyrazolo[3,4-d]-pyrimidin-4-amine, impliquant l'arylation de 1-(pipéridin-3-yl)pyrazolo[3,4-d]pyrimidin-4-amine N-protégée en présence d'un catalyseur au palladium, d'un ligand contenant de l'azote et d'une base, avec le retrait consécutif des groupes protecteurs par des procédés connus. (Formule (II))
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-15-98 | 2015-08-31 | ||
LVP-15-98A LV15201B (lv) | 2015-08-31 | 2015-08-31 | Ibrutiniba izejvielas iegūšanas paņēmiens |
PCT/LV2015/000009 WO2017039425A1 (fr) | 2015-08-31 | 2015-11-13 | Procédé de préparation de précurseur d'ibrutinib |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2987708A1 true CA2987708A1 (fr) | 2017-03-09 |
CA2987708C CA2987708C (fr) | 2022-08-02 |
Family
ID=54754721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2987708A Active CA2987708C (fr) | 2015-08-31 | 2015-11-13 | Procede de preparation de precurseur d'ibrutinib |
Country Status (4)
Country | Link |
---|---|
CA (1) | CA2987708C (fr) |
GB (1) | GB2556535B (fr) |
LV (1) | LV15201B (fr) |
WO (1) | WO2017039425A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107674079B (zh) * | 2017-09-27 | 2019-12-13 | 黑龙江珍宝岛药业股份有限公司 | 一种伊布替尼的合成方法 |
CN113200986A (zh) * | 2021-04-29 | 2021-08-03 | 湖南华腾制药有限公司 | 一种伊布替尼中间体的制备方法 |
CN114940678B (zh) * | 2021-09-26 | 2023-02-07 | 上海贵之言医药科技有限公司 | 一种吡唑并嘧啶酯类化合物 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080007621A1 (en) | 2006-07-06 | 2008-01-10 | Sbc Knowledge Ventures, Lp | System and method of controlling access to an entrance |
SG10201508035TA (en) | 2007-03-28 | 2015-10-29 | Pharmacyclics Inc | Inhibitors of bruton's tyrosine kinase |
AU2008323694A1 (en) | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
US9273028B2 (en) | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
US9376438B2 (en) * | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
KR102311329B1 (ko) * | 2013-03-15 | 2021-10-14 | 얀센 파마슈티카 엔.브이. | 약제를 제조하기 위한 방법 및 중간체 |
-
2015
- 2015-08-31 LV LVP-15-98A patent/LV15201B/lv unknown
- 2015-11-13 WO PCT/LV2015/000009 patent/WO2017039425A1/fr active Application Filing
- 2015-11-13 GB GB1800657.7A patent/GB2556535B/en active Active
- 2015-11-13 CA CA2987708A patent/CA2987708C/fr active Active
Also Published As
Publication number | Publication date |
---|---|
LV15201A (lv) | 2017-03-20 |
GB2556535A (en) | 2018-05-30 |
CA2987708C (fr) | 2022-08-02 |
GB2556535B (en) | 2020-10-14 |
WO2017039425A1 (fr) | 2017-03-09 |
LV15201B (lv) | 2017-07-20 |
GB201800657D0 (en) | 2018-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105884781B (zh) | 一种枸橼酸托法替布的制备方法 | |
Barluenga et al. | IPy2BF4-promoted intramolecular addition of masked and unmasked anilines to alkynes: direct assembly of 3-iodoindole cores | |
EP3983404B1 (fr) | Composés pyrazole disubstitués utilisés en tant qu'inhibiteurs de cétohexokinase | |
CN110041333B (zh) | 溴结构域抑制剂化合物及其用途 | |
Brown et al. | Total Synthesis of Ustiloxin D Utilizing an Ammonia–Ugi Reaction | |
Chang et al. | Parallel synthesis of natural product-like polyhydroxylated pyrrolidine and piperidine alkaloids | |
Marra et al. | Toward the identification of neuroprotective agents: g-scale synthesis, pharmacokinetic evaluation and CNS distribution of (R)-RC-33, a promising SIGMA1 receptor agonist | |
CA2987708C (fr) | Procede de preparation de precurseur d'ibrutinib | |
Bálint et al. | Structure‐Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition | |
Yan et al. | Conformation-induced regioselective and divergent opening of epoxides by fluoride: facile access to hydroxylated fluoro-piperidines | |
US8158798B2 (en) | Coupling process for preparing quinolone intermediates | |
Wang et al. | Catalytic stereospecific allylation of protected hydrazines with enantioenriched primary allylic amines | |
WO2017163257A1 (fr) | Procédé de préparation d'un dérivé lh-pyrazolo[3,4-d] pyrimidine pur | |
TWI558706B (zh) | A tricyclic compound and a tricyclic compound which can be produced by the production method | |
CN113527300B (zh) | 布鲁顿酪氨酸蛋白激酶抑制剂 | |
Du et al. | Discovery of a PROTAC degrader for METTL3-METTL14 complex | |
CN109796457B (zh) | 一种2-(3-(氮杂环丁烷-3-基)哌啶-1-基)乙基-1-醇的制备方法及其应用 | |
EP2050735A1 (fr) | Méthode de production d'un composé 3-amino-azoté optiquement actif | |
EA019031B1 (ru) | Способ получения 6-{4-[3-((r)-2-метилпирролидин-1-ил)пропокси]фенил}-2н-пиридазин-3-она и его фармацевтически приемлемой соли | |
Kishore et al. | Novel synthesis of carbohydrate fused α-amino γ-lactams and glycopeptides by NIS mediated ring opening of donor–acceptor substituted cyclopropanes | |
Delarue-Cochin et al. | Synthesis of new aza-analogs of staurosporine, K-252a and rebeccamycin by nucleophilic opening of C 2-symmetric bis-aziridines | |
CN110628740A (zh) | 一类模拟dot1l多肽的拟肽类小分子化合物的制备方法和用途 | |
Hu et al. | Small change for big improvement in the preparation of the key intermediate N 1, N 3-disubstituted 1, 3, 5-triazone of ensitrelvir | |
CN102712600A (zh) | 制备吲唑-3-甲酸和n-(s)-1-氮杂双环[2.2.2]辛-3-基-1h-吲唑-3-甲酰胺盐酸盐的方法 | |
Sun et al. | Novel mutual pro-drugs of 2′, 3′-dideoxyinosine with 3-octadecyloxy-propane-1, 2-diol by straightforward enzymatic regioselective synthesis in acetone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200715 |
|
EEER | Examination request |
Effective date: 20200715 |
|
EEER | Examination request |
Effective date: 20200715 |
|
EEER | Examination request |
Effective date: 20200715 |